Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia.

Clinical trial NCT06531018 · RECRUITING

Trial details

NCT number: NCT06531018
Sponsor: Renata PLC
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Primary Immune Thrombocytopenia

Start date: 2025-02-07
Primary completion: 2025-08-31
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.